Abivax SA Announces Results of 2026 Annual General Meeting and Director Renewals

Abivax SA held its Annual Ordinary and Extraordinary General Meeting of shareholders on May 11, 2026. Shareholders approved all 33 proposed resolutions, including the approval of the company's financial statements for the fiscal year ended December 31, 2025. Key outcomes included the renewal of director terms for Sylvie Grégoire, June Lee, and Troy Ignelzi. The meeting also approved compensation policies for the Chair of the Board, Chief Executive Officer Marc de Garidel, and other directors. Additionally, shareholders granted several delegations of authority to the Board of Directors for financial transactions, including authorizations to increase share capital through various means such as public offers, qualified investor placements, and an "At-The-Market" (ATM) program. The board was also authorized to grant share subscription options, warrants, and free shares. The participation rate for the meeting was 86.06% of the voting rights.